Trial Profile
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Pomaglumetad methionil (Primary) ; Risperidone
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly and Company
- 11 Jul 2012 Primary endpoint 'Positive-and-Negative-Syndrome-Scale' has not been met.
- 30 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.